Dato-DXd: AstraZeneca and Daiichi Sankyo's Unwavering ADC Pursuit

AstraZeneca and Daiichi Sankyo's investigational antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) has encountered challenges in two pivotal Phase 3 cancer trials.

September 27, 2024

The Radiopharmaceutical Revolution

The radiopharmaceutical industry is witnessing a surge of activity and investment, underscoring the immense potential of these cutting-edge therapies in the fight against cancer.

September 27, 2024

Biotech Funding Rollercoaster: Tracking Valuation Shifts from Seed to IPO

In September, 3 biotechs IPOd on the same day, and their filings revealed an interesting insight: how much money did earlier venture investors make at the IPO?

September 25, 2024

Top 10 BioPharma Market Cap Gains: September 2023 vs. 2024

In the past 12 months, several BioPharma companies experienced substantial gains in market capitalization, driven by continued performance of GLP-1s and improved results in oncology.

September 25, 2024

Biotech IPO Trifecta: A Resurgence of Innovation and Investment

In a rare tripleheader day, three biotechnology companies successfully went public, raising a combined $750 million: Bicara Therapeutics, Zenas BioPharma, and MBX Biosciences.

September 23, 2024

Post-Keytruda: Potential Growth Drivers for Merck

As Keytruda’s LOE approaches in 2028, Merck continues to strengthen its pipeline. Here are some key developments shaping Merck's future:

September 23, 2024

Select Eli Lilly U.S. Patent Expiries

Eli Lilly has seen a growth surge thanks to the success of its GLP-1s, which enjoy patent protection well into the 2030s. The rest of its portfolio is more nuanced - here’s a closer look at key patent expiries in key therapeutic areas:

September 20, 2024

Moderna's Strategic Shift: Paving the Way for Diversification and Profitability

Moderna’s stock moved significantly last week after the company unveiled a reprioritization plan to navigate commercial challenges at its recent R&D day. Here’s a deeper dive into Moderna’s goals to establish a diversified portfolio:

September 20, 2024

YoY Growth of Top 10 BioPharma companies by Q2 2024 Sales

The top 10 BioPharma companies by sales in Q2 saw an 8% YoY growth overall, with Eli Lilly leading the pack in YoY growth rate. Several non-Top 10 companies also exhibited notable growth. Here is a look at some key growth drivers:

September 11, 2024

Pfizer Delivers Robust Q2 2024 Performance, Raises Full-Year Guidance

Pfizer raised its full-year sales guidance by $1 billion after announcing Q2 2024 results, with $13.3 billion in revenues and 3% YoY operational growth despite anticipated COVID-related sales declines. Here are some of the notable growth drivers.

September 11, 2024

Roche's Pharmaceutical Division Performance in Q2 YoY

Roche's Pharmaceutical Division witnessed strong growth in Q2 2024, driven by the performance of its blockbuster therapies. This report provides an in-depth analysis of the key drivers behind this success and the company's strategic initiatives to maintain its leadership position in various therapeutic areas.

September 11, 2024

Notable Biopharma Fundraises in August: Powering Promising Treatments

In August, ~20 notable Biotech fundraises soaked up a combined $1.2B, helping power work on several promising treatments across various indications and modalities. Here are some highlights:

September 09, 2024

Epidemiologies of Oncology: Insights from AstraZeneca and Novartis

Oncology is uniquely complex because of the large number of variations, each of which often requires a different type of medicine. Here’s a look at the epidemiology of breast and lung cancer, and some leading treatments:

September 09, 2024

Massachusetts Biopharma Industry Snapshot 2024

Last week, MassBio published their annual biopharma Industry Snapshot covering key topics including funding and employment. Despite positive momentum in capital markets, MA-based biotechs saw a dip in VC funding to the lowest point since 2019. Here are other highlights:

September 05, 2024

New EMA Medicine Approvals Through August 2024

In the first eight months of 2024, the EMA approved 45 new drugs, keeping pace with the 77 it approved in 2023. Here’s a dive into the latest EMA approvals initiative and the details of new approvals:

September 04, 2024

Revolutionizing Cancer Treatment: The Emergence of mRNA Vaccines

BioNTech recently launched Phase 1 trials for its mRNA lung cancer vaccine, one of ~70 clinical trials exploring using mRNA vaccines against cancer. Here’s a closer look at mRNA vaccines as a potential cancer therapy:

September 04, 2024

Crowning Achievements: Recent Royalty Deals in BioPharma

Are royalty deals the new savior of BioPharma cash burn? Challenging capital markets have made these deals more attractive to all players:

September 03, 2024

BioPharma's Direct-to-Consumer Evolution

Last week, Pfizer launched a new DTC website called Pfizer for All, highlighting increasing efforts by BioPharma companies to engage directly with consumers, who neither write checks or make prescribing decisions:

September 03, 2024

Atopic Dermatitis Landscape

Dupixent is now the world’s third biggest selling medicine, and much of its revenue comes from atopic dermatitis. The field is increasingly crowded, with AbbVie’s Rinvoq one of several challengers pushing to raise the bar:

August 29, 2024

How Much Do Large BioPharma Companies Spend on Capex?

Capital expenditures are usually overlooked in the biopharma world, because the industry is relatively capital-light. However, the race to produce GLP-1s and the increasing complexity of new types of medicines are changing this perspective.

August 29, 2024

Top 15 Immunology Medicines by Q2 2024 Sales

Immunology ranks as the second-largest segment in the biopharmaceutical industry by sales, following oncology. This analysis delves into the 15 top-selling immunology medicines in Q2, highlighting the key growth drivers behind their performance:

August 29, 2024

Top 10 BioPharma Companies by Revenue Q2 2024

Several biopharmaceutical companies have reported an increase in revenue and earnings guidance with their second-quarter earnings. This article takes a closer look at the ten largest companies by revenue and explores the factors behind their financial results.

August 29, 2024

Top 15 Oncology Medicines by Q2 2024 Sales

Oncology remains the largest segment of the BioPharma industry, hosting many of the industry’s top-selling medicines. Several key drugs are facing LOEs soon. Here’s a closer look behind key catalysts driving development and growth:

August 29, 2024

Roche: 10 Year Sales Evolution

Roche has achieved steady growth in the last several years, yet underneath, it has undergone significant change. Here are a few highlights about how it has evolved over the last decade:

August 21, 2024

Top 10 Medicines by Q2 2024 Sales

All major public BioPharma companies have reported Q2 results. Here's a look behind the world's 10 top-selling medicines:

August 21, 2024

IRA's First 10: How Much Revenue is at Stake?

In the initial 10 medicines under the IRA, there is a huge variance in terms of how much each company's revenue is dependent on that medicine. Here's a fresh take on the relative impact:

August 21, 2024

Alzheimer's Disease Landscape

Last month, the EMA rejected Biogen's Leqembi, despite the FDA’s previous approval, citing major safety risks that involve ARIA (brain bleeding and/or swelling). Here’s a closer look at Leqembi and other promising Alzheimer’s treatments:

August 15, 2024

Lilly and Novo: How do GLP-1 Sales Compare? (Q2 '24)

Last week, both Eli Lilly and Company and Novo Nordisk reported quarterly results, where the focus continued to be on the companies' GLP-1 medicines. Here are some notable updates on manufacturing expansion, intl. sales, and access.

August 14, 2024

AstraZeneca's Top 10 Medicines by Sales in Q2 '24

AstraZeneca reported quarterly earnings a few days back, demonstrating continued strong growth, especially in oncology. Here’s a more detailed look at some of the highlights:

August 12, 2024

Sanofi Revenue by Category - Q2 '24 Earnings Recap

Sanofi announced Q2 results recently, including continued strong growth from Dupixent, along with several new launches and pipeline updates. Here's a deeper dive:

August 12, 2024

BMS Top 10 Medicines by Sales in Q2 '24

Bristol Myers Squibb (BMS) reported its second-quarter earnings last week, showcasing strong growth in its newer medicines portfolio and better-than-expected results for its mature medicines. Here is a closer look at BMS's performance for the quarter:

August 02, 2024

Top 10 BioPharma Companies by Revenue (2003 to 2023)

Over the past 20 years, the top 10 Biopharma companies have almost doubled revenue. Yet, there has been considerable variance among companies. Here's a closer look behind some of the most notable changes.

August 01, 2024

Top 20 Companies by Market Cap (2003 vs. 2024)

In 2003, BioPharma accounted for nearly a quarter of the market cap within the world’s 20 most valuable companies. Today, BioPharma makes up only 5% of the top 20. Here are some driving causes of this change.

August 01, 2024

AbbVie Q2 Earnings: Immunology Strength Overshadows Aesthetics Challenges

Immunology Strength Overshadows Aesthetics Challenges AbbVie reported strong Q2 earnings, driven by immunology drugs Skyrizi and Rinvoq. The company raised guidance for both, with Skyrizi now expected to hit 11B in global sales and Rinvoq 5.7B. Skyrizi and Rinvoq have a combined 40% share of the US Crohn's market. However, aesthetics remained a weak spot with flat sales, as Juvéderm declined due to economic headwinds.

July 29, 2024

The Shifting Spending Priorities of Big Pharma

Explore the shifting spending priorities of big pharma over the past 30 years, including the steep decline in sales & marketing costs and surge in R&D expenditures to develop new drugs.

July 26, 2024

The Prize of the Eyes: Eylea & Vabysmo in Opthalmology

Roche held an Ophthalmology-focused investor event today at the end of the annual American Society of Retina Specialists Meeting in Stockholm, and provided some interesting insights on Vabysmo’s performance vs. Eylea:

July 23, 2024

J&J's Q2 Earnings and Key Milestones in Immunology and Oncology

Johnson & Johnson (J&J) recently reported its Q2 earnings, providing insights into the performance of its core divisions, Innovative Medicines and MedTech, following the spin-off of its consumer arm, Kenvue.

July 22, 2024

Small Molecule GLP-1 Overview

Two key GLP-1 updates came out in the last week, both on small molecules: Pfizer's update on danuglipron, and Roche's topline results yesterday on CT-996, which caused shares of competitors to drop sharply - here's the recap:

July 18, 2024

Recap of Recent Radiopharmaceutical Deals

Radiopharmaceuticals are one of the most dynamic segments of BioPharma. Here is a deep dive into some notable deals, and how the biggest companies are approaching the space.

July 15, 2024

The Constant Evolution of Biopharma: A Decade of Transformation

Biopharma companies reinvent themselves every decade, driven by innovation and portfolio changes. Learn about the shifting best-sellers, impacts on sales teams, brand awareness, and strategic decisions in the industry.

July 08, 2024

Top 15 Immunology Drugs by Sales of Q1 '24

Explore the shifting landscape of the immunology market as top-selling drugs face varying futures. Humira's sales slow but stabilize, with AbbVie's Skyrizi and Rinvoq picking up momentum, projecting a combined sales forecast of $27B by 2027. Meanwhile, J&J's Stelara braces for generic competition in early 2025, and Dupixent's sales soar, potentially expanding indications to include COPD.

July 01, 2024

Novartis Navigates Patent Cliff with Robust Pipeline and Strategic Focus

Facing upcoming patent expirations, Novartis is reinforcing its pipeline with promising drugs like Kisqali and Pluvicto. Despite challenges, including complex manufacturing for radioligand therapies, the company's strategic focus and recent divestitures position it well to manage future competition.

June 25, 2024

Top 10 Biopharma Fundraises in April 2024

In April 2024, the top 10 biopharma fundraising rounds totaled more than $2B, yet more than half the haul was from just two companies

May 14, 2024

Which Large Pharma Companies Spend the Most on M&A?

In the past 2 years, 10 of the largest biopharma companies spent a combined $170 BILLION on M&A. But why do some spend much more than others?

May 07, 2024

Top 15 Biopharma Companies by Oncology Sales

Oncology is the largest single therapeutic area within the global biopharma market, worth over $200B. While a lot of analysis is focused on sales of individual drugs, it is also helpful to take a look at oncology sales by company overall to help paint a fuller picture.

May 07, 2024

The 15 Biggest Biotech and Pharma Fundraisings in Q1 2024

The 15 largest biotech fundraisings picked up ~$2.8B in Q1, showing that capital markets are seeing improved sentiment after 2 years of difficulty.

May 03, 2024

Top 10 Pharma Companies by Revenue in 2023

The 10 largest pharma companies generated close to $500 billion in revenue in 2023. Over the past 10 years, they grew their sales by ~$160B through a combination of blockbuster products and transformational M&A deals.

May 03, 2024

Upcoming Patent Expirations and LOEs for the 15 Biggest Drugs by Sales

The biopharma industry has ~$200B in revenue at risk in the next 5 years, including 8 out of the top 15 drugs. Here's a closer look behind the upcoming patent cliff:

April 23, 2024

Top 10 Biopharma M&A Deals in Q1 2024

The 10 biggest biopharma deals of Q1 '24 were worth ~$17 billion. Here's a look at key trends behind them:

April 23, 2024

Top 15 Oncology Drugs by Sales in 2023

Oncology is the single largest market in the global biopharma industry, worth over $200B. Here's a look at the top 15 drugs in the space, and some insights behind the numbers:

April 15, 2024

Top 10 Immunology Drugs by Worldwide Sales in 2023

The top 10 immunology drugs generated more than $70 billion in revenue. last year. Here are some surprising trends behind the second biggest market in biopharma

April 13, 2024

Top 15 Drugs by Worldwide Sales in 2023

The list of the world's 15 top selling drugs in 2023 is led by Merck's oncology powerhouse Keytruda, which achieved a record of $25 billion in revenue last year.

March 22, 2024

Race for GLP-1 Obesity Drugs Heats Up

13 years after Roche halted its GLP-1 drug trials due to side effects, it's making a $3.1B acquisition to get back in the weight loss game.

January 20, 2024

How Drug Pricing in the US Compares to Other Countries

New weight loss drugs like Ozempic, Wegovy and Zepbound have been on fire - but how does pricing in the US compare to other countries? It’s no secret that drugs cost more in the US than in other developed economies, and the Inflation Reduction Act’s provision to allow Medicare to negotiate drug prices has reignited that debate.

January 20, 2024

AI Drug Discovery Continues to Show Strength, but Some Win More Than Others

While AI drug discovery has huge promise, achieving the biggest wins involves not just the best models, but old-fashioned persistence and risk taking.

January 20, 2024

Big Pharma Partnerships in 2023: A Comprehensive Overview

Facing a landscape where many blockbuster drugs are nearing or have reached the end of their exclusivity, large biopharma leaders are increasingly turning to collaborations to refill their pipelines with promising therapeutics.

January 19, 2024